A5030569507- Brain Metastases and Treatment
- Lymphoma Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Breast Cancer Treatment Studies
- Lung Cancer Treatments and Mutations
- Glioma Diagnosis and Treatment
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Head and Neck Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
- Radiopharmaceutical Chemistry and Applications
- Meningioma and schwannoma management
- Gastric Cancer Management and Outcomes
- HER2/EGFR in Cancer Research
- Esophageal Cancer Research and Treatment
- Breast Lesions and Carcinomas
- Esophageal and GI Pathology
- T-cell and Retrovirus Studies
- Advances in Oncology and Radiotherapy
- MRI in cancer diagnosis
- Gene Regulatory Network Analysis
- Chronic Myeloid Leukemia Treatments
- Viral-associated cancers and disorders
- Advanced Breast Cancer Therapies
City Of Hope National Medical Center
2023-2024
City of Hope
2023-2024
Hoag Memorial Hospital Presbyterian
2021
Newport (United States)
2017-2020
University of Colorado Denver
2006-2009
University of Colorado Cancer Center
2006-2008
University of Colorado Health
2006-2008
University of Colorado Anschutz Medical Campus
2007-2008
University of Colorado Hospital
2006
Abstract BACKGROUND. Randomized trials provide evidence for improved outcomes with postmastectomy radiotherapy (PMRT) in high‐risk patients. It has been suggested that patients T3N0 breast cancer represent a favorable subgroup which PMRT renders little benefit. In the current study, authors used United States population database to evaluate this subgroup. METHODS. The cause‐specific survival (CSS) and overall (OS) of women T3N0M0 Surveillance, Epidemiology, End Results after mastectomy...
Non-small cell lung cancer is a devastating disease and with the advent of targeted therapies molecular testing, decision-making process has become complex. While established guidelines pathways offer some guidance, they are difficult to utilize in busy community practice not always implemented community. The rationale study was identify cohort patients adenocarcinoma at City Hope site (n = 11) their case studies develop framework utilizing fast-and-frugal tree (FFT) heuristics. Most had...
In the context of oligometastatic renal cell carcinoma (RCC), local treatment with stereotactic body radiotherapy (SBRT) may improve oncologic outcomes. However, location and size can often pose a technical challenge in standard SBRT delivery, dose is potentially limited by nearby organs at risk (OARs). Online adaptive (oART) improves radiation delivery personalizing high-dose fractions to account for daily stochastic variations patient anatomy or setup. The oART process aims maximize tumor...
Background/Objectives: The 8th edition of the American Joint Committee on Cancer integrates histology and biomarker status with anatomic extent in breast cancer (BC) pathologic prognostic staging (PPS). However, PPS IB includes locally advanced hormone-receptor-positive/HER2-negative (LA-HR+/HER2-) early-stage triple-negative BC (ES-TNBC). Previous research shows that increased nodal involvement is a critical predictor worse prognosis, raising questions about whether biological subtype or...
Objective To examine the relationship between prescribed target dose and to healthy neurovascular structures in patients with vestibular schwannomas treated stereotactic radiosurgery (SRS). Study Design Case series chart review. Setting SRS center from 2011 2013. Subjects Twenty at Methods were included. The average radiation delivered (eg, carotid artery, basilar facial nerve, trigeminal cochlea) was analyzed. Results who fused computed tomography/magnetic resonance imaging–guided included...
Brachytherapy treatment consists of the insertion radioactive sources into tissue to deliver radiotherapy directly tumor. Early utilizing this method required intra-operative placement 15–20 catheters by radiation oncologist, a highly specialized procedure which limited its widespread use despite encouraging results from first clinical trial and benefits patient receiving only 2 cm beyond borders lumpectomy cavity ability complete component breast conserving in 4–5 days, instead usual 4–6...